8-K: ATAI & Beckley Psytech Report Positive BPL-003 Phase 2a Data

ATAI Life Sciences and Beckley Psytech announced positive Phase 2a data for BPL-003, demonstrating improved outcomes with a two-dose regimen in treatment-resistant depression.

Summary

• An open-label Phase 2a study of BPL-003 (intranasal mebufotenin benzoate) in 12 patients with treatment-resistant depression (TRD) evaluated a two-dose induction regimen (8 mg followed by 12 mg two weeks later).
• Following the first 8 mg dose, patients experienced a mean MADRS reduction of 13.3 points from baseline at Day 2 and 12.9 points at Day 8.
• One week after the second 12 mg dose, the mean MADRS score showed a total reduction of 19.0 points from baseline, with sustained antidepressant effects observed through Week 12 (13.7 points reduction from baseline).
• The second dose of BPL-003 increased remitter rates from 25% one week after the initial 8 mg dose to 50% at Week 8 (six weeks after the second dose) and 42% at Week 12.
• BPL-003 was generally well-tolerated, with all adverse events classified as mild to moderate, and no severe or serious drug-related adverse events reported.
• Patients met discharge readiness criteria within two hours after dosing for both administrations, indicating practical administration.
• Doses used in this study are consistent with active doses in Beckley Psytech's Phase 2b study of BPL-003, which reported positive topline findings in July.
• Data from the open-label extension (OLE) of the Phase 2b study, evaluating a 12 mg dose eight weeks after the initial dose, is expected in October.
• ATAI and Beckley Psytech are finalizing plans to engage with the FDA and other regulatory agencies to discuss the design of the Phase 3 clinical trial for BPL-003, with initiation expected in the first half of 2026.

Sentiment

Score: 9

Explanation: The reported Phase 2a data for BPL-003 shows rapid, durable, and enhanced antidepressant effects with a favorable safety profile, significantly de-risking the asset and strengthening its potential for commercialization in a high-need area.

Positives

• Rapid and durable antidepressant effects were observed, with a mean MADRS reduction of 13.3 points at Day 2 and a total 19.0-point reduction from baseline one week after the second dose.
• The two-dose regimen significantly improved response and remission rates, with remitter rates doubling from 25% after the first dose to 50% at Week 8.
• BPL-003 demonstrated a strong and consistent tolerability profile, with all adverse events being mild to moderate and no severe or serious drug-related adverse events.
• The practical administration, allowing patients to meet discharge readiness within two hours, reinforces its potential for integration into psychiatric treatment paradigms.

Risks

• The proposed acquisition of Beckley Psytech by atai Life Sciences may not be completed in a timely manner or at all, including risks related to obtaining required shareholder approvals.
• There is a risk of failure to realize the anticipated benefits of the proposed transaction.
• Conditions to the consummation of the proposed transaction may not be satisfied or waived.
• The share purchase agreement could be terminated due to various events, changes, or circumstances.
• The announcement or pendency of the proposed transaction could affect atai's ability to retain and hire key personnel, or impact its operating results and business generally.
• General risks described in atai's most recent Annual Report on Form 10-K and the Registration Statement on Form S-4 may also affect future results.

Future Outlook

Expectations include the readout of Phase 2b open-label extension study data in October, finalization of plans for engaging with the FDA and other regulatory agencies to discuss Phase 3 trial design, and the anticipated initiation of Phase 3 trials in the first half of 2026. The all-share transaction combining atai Life Sciences and Beckley Psytech is expected to close in the second half of 2025.

Management Comments

• Cosmo Feilding Mellen, CEO and Co-Founder of Beckley Psytech, stated: "These results underline BPL-003s potential to offer a rapid, well-tolerated and durable treatment option for patients with treatment-resistant depression. They suggest that a second dose of BPL-003 not only maintains, but potentially deepens, antidepressant effects while remaining well-tolerated."
• Srinivas Rao, CEO and Co-Founder of atai Life Sciences, commented: "This proof-of-concept study provides compelling evidence that a two-dose induction regimen for BPL-003 may optimize outcomes for patients with treatment-resistant depression. This dosing approach could be further explored in Phase 3 studies, subject to discussions with regulators."

Industry Context

BPL-003 addresses a significant unmet need in treatment-resistant depression (TRD), a condition affecting nearly 300 million people globally, with up to 50% of those living with depression experiencing TRD. The positive data positions atai and Beckley Psytech as potential leaders in developing rapid-acting, durable, and convenient psychedelic-based mental health treatments, aligning with a broader industry trend towards innovative therapies for neuropsychiatric disorders.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks for similar treatments. It notes that the tolerability profile is consistent with previously reported studies of BPL-003.

Stakeholder Impact

• **Shareholders:** Positive clinical trial results for a key pipeline asset are likely to increase investor confidence and potentially the company's valuation.
• **Patients:** The data suggests BPL-003 could offer a rapid, durable, and well-tolerated treatment option for individuals suffering from treatment-resistant depression, addressing a significant unmet medical need.
• **Employees:** The positive progress in drug development and the ongoing merger could provide stability and new opportunities within the combined entity.

Next Steps

• Data readout from the open-label extension (OLE) of the Phase 2b study for BPL-003 is expected in October.
• Finalizing plans to engage with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to discuss the design of the Phase 3 clinical trial for BPL-003.
• Initiation of Phase 3 trials for BPL-003 is expected in the first half of 2026, pending FDA feedback.
• The all-share transaction combining atai Life Sciences and Beckley Psytech is expected to close in the second half of 2025.

Key Dates

Recommendation

The positive Phase 2a data for BPL-003, demonstrating rapid, durable, and enhanced antidepressant effects with a two-dose regimen, significantly de-risks the development pathway for this treatment in treatment-resistant depression. The improved response and remission rates, coupled with a strong tolerability profile and practical administration, suggest a high potential for BPL-003 to address a substantial unmet medical need. This positive clinical milestone, combined with the ongoing acquisition of Beckley Psytech, strengthens atai's pipeline and market position, making it an attractive investment.

Keywords

ATAI Life Sciences, Beckley Psytech, BPL-003, Treatment-Resistant Depression, TRD, Psychedelic Therapy, Clinical Trial, Phase 2a, Mebufotenin Benzoate, Mental Health, Drug Development, Biopharmaceutical, NASDAQ: ATAI